01 Emergence of Circular RNA Therapies The development of circular RNA and self-amplifying RNA platforms is a key trend for the market. For instance, in June 2024, Orna Therapeutics advanced its circRNA-based therapy ORN-101 into an early-stage trial for oncology. In parallel, Imperial College London’s saRNA vaccine work has shown robust immune responses at very low doses, underscoring dose efficiency and scalable manufacturing potential. This showcases that next-generation RNA therapies are advancing, fueling investor interest and driving the growth of the RNA therapeutics market.
02 Strategic Collaborations between Key Market Players Strategic collaboration is a key trend shaping the clinical innovations in RNA therapies. For instance, in May 2024, AbbVie Partnered with ADARx to co-develop next-generation siRNA therapies targeting neuroscience, immunology, and oncology indications. Under this deal, ADARx received a USD 335 million upfront payment for its RNA discovery platform. Therefore, through this collaboration, AbbVie can accelerate the development of siRNA, which, in return, supports the market growth.
01 Surge in Incidences of Cancer and Genetic Diseases The rise in prevalence of cancer and genetic diseases is creating a strong demand for advanced therapies.Additionally, rare genetic diseases are rapidly surging; Alnylam’s Onpattro, the first approved RNA therapy, addresses these medical needs. These developments show that a growing patient pool is driving the product adoption.
02 Strong Funding Support from the Government and Academic Institutes Increasing funding from government and academic institutes is a major factor driving the market growth.These funding activities show that the government is making RNA innovation a strategic priority, which is expanding manufacturing capacity and accelerating market growth.
01 High Development and Manufacturing Costs The increasing cost of developing novel RNA therapies is restraining the market growth to some extent. Manufacturing mRNA and RNAi treatments requires high-purity nucleotides, specialized enzymes, and lipid nanoparticles.
01 Expanding Pipeline of mRNA and RNAi Therapies Leading vaccine developers have shifted their focus from only vaccines to developing RNA-based treatments for cancer, rare diseases, and other metabolic diseases. As more of these therapies move through clinical trials and gain approval, more treatment options will be available, making RNA therapeutics a major part of healthcare.
March 2026 Moderna expanded its mRNA therapeutics pipeline through continued research and development initiatives focused on advancing RNA-based medicines for infectious diseases, oncology, and rare disease applications.
September 2025 Alnylam Pharmaceuticals expanded its RNA interference (RNAi) therapeutics portfolio with new clinical and commercial initiatives aimed at developing innovative treatments for genetic and chronic diseases.
May 2025 Ionis Pharmaceuticals advanced its antisense RNA therapeutics pipeline through new clinical development programs targeting neurological, cardiovascular, and rare disease indications.